Compare BBSI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | SNDX |
|---|---|---|
| Founded | 1965 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 748.3M | 1.8B |
| IPO Year | 1994 | 2014 |
| Metric | BBSI | SNDX |
|---|---|---|
| Price | $29.86 | $20.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $42.67 | $38.69 |
| AVG Volume (30 Days) | 160.9K | ★ 1.7M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | 5.05 | ★ 11.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $920,432,000.00 | $172,352,000.00 |
| Revenue This Year | $6.59 | $107.19 |
| Revenue Next Year | $6.05 | $41.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.50 | ★ 627.84 |
| 52 Week Low | $25.33 | $8.59 |
| 52 Week High | $49.65 | $25.59 |
| Indicator | BBSI | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 42.05 |
| Support Level | $29.54 | $19.35 |
| Resistance Level | $30.61 | $22.33 |
| Average True Range (ATR) | 1.03 | 1.06 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 53.29 | 37.80 |
Barrett Business Services Inc is a provider of business management solutions for small and mid-sized companies through a platform that combines management consulting expertise with human resource tools to help business owners manage and operate their businesses more effectively. The company has two categories of services: Professional Employer Services (PEO) and Staffing. The majority of revenue is derived from the Professional Employer Services segment, which provides clients with human resource advisory services, HRIS access, retirement plans, a learning management system, and a web-based technology platform, myBBSI.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.